Management of Bleeding Associated with New Oral Anticoagulants

Massimo Franchini, Carlo Bonfanti, Pier Mannuccio Mannucci

Research output: Contribution to journalArticlepeer-review


In the last few years, a great improvement in the management of clinical thromboembolism has been made thanks to the availability of novel oral anticoagulants. These drugs, which act by directly inhibiting thrombin (dabigatran) or activated factor X (apixaban, rivaroxaban, and edoxaban), offer several practical advantages over the traditional vitamin K antagonists (VKA), such as a more predictable anticoagulant effect with no need for routine coagulation monitoring and a limited drug and food interaction. Several phase III clinical trials have now been completed, overall demonstrating that non-VKA oral antagonists (NOACs) are at least as efficacious and safe as VKA in the prevention and treatment of thromboembolism. Nevertheless, patients receiving NOACs represent a new challenge because no antidotes are currently available for these drugs. In this review, after a description of the main pharmacologic characteristics and the main results of the clinical trials of NOACs, we will focus on the management of bleeding associated with these anticoagulant agents. A treatment algorithm of NOACs-associated bleeding is finally provided, with the aim of helping physicians in their daily care activity.

Original languageEnglish
Pages (from-to)788-801
Number of pages14
JournalSeminars in Thrombosis and Hemostasis
Issue number7
Publication statusPublished - Sept 26 2015


  • antidote
  • apixaban
  • bleeding
  • dabigatran
  • edoxaban
  • new oral anticoagulants
  • rivaroxaban

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Management of Bleeding Associated with New Oral Anticoagulants'. Together they form a unique fingerprint.

Cite this